MX2022012447A - Vacuna inactivada contra el virus sars-cov-2. - Google Patents

Vacuna inactivada contra el virus sars-cov-2.

Info

Publication number
MX2022012447A
MX2022012447A MX2022012447A MX2022012447A MX2022012447A MX 2022012447 A MX2022012447 A MX 2022012447A MX 2022012447 A MX2022012447 A MX 2022012447A MX 2022012447 A MX2022012447 A MX 2022012447A MX 2022012447 A MX2022012447 A MX 2022012447A
Authority
MX
Mexico
Prior art keywords
cov
virus vaccine
inactivated sars
sars
inactivated
Prior art date
Application number
MX2022012447A
Other languages
English (en)
Inventor
Robert Schlegl
Andreas Meinke
Jürgen Heindl-Wruss
Michael Möhlen
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Priority claimed from PCT/EP2021/058974 external-priority patent/WO2021204825A2/en
Publication of MX2022012447A publication Critical patent/MX2022012447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Aquí se describen vacunas contra el SARS-CoV-2 y composiciones y métodos para producir y administrar dichas vacunas a sujetos que las necesitan.
MX2022012447A 2020-04-06 2021-04-06 Vacuna inactivada contra el virus sars-cov-2. MX2022012447A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202118 2020-10-15
EP20211853 2020-12-04
EP21154647 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160913 2021-03-05
PCT/EP2021/058974 WO2021204825A2 (en) 2020-04-06 2021-04-06 INACTIVATED SARS-CoV-2 VIRUS VACCINE

Publications (1)

Publication Number Publication Date
MX2022012447A true MX2022012447A (es) 2022-10-27

Family

ID=79566178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012447A MX2022012447A (es) 2020-04-06 2021-04-06 Vacuna inactivada contra el virus sars-cov-2.

Country Status (14)

Country Link
US (1) US20240293531A1 (es)
EP (1) EP3955959A2 (es)
JP (1) JP2023520521A (es)
KR (1) KR20220164500A (es)
CN (1) CN115768469A (es)
AU (1) AU2021253605A1 (es)
BR (1) BR112022020100A2 (es)
CA (1) CA3168784A1 (es)
CL (1) CL2022002365A1 (es)
CO (1) CO2022013715A2 (es)
EC (1) ECSP22072590A (es)
IL (1) IL296072A (es)
MX (1) MX2022012447A (es)
ZA (1) ZA202209826B (es)

Also Published As

Publication number Publication date
CA3168784A1 (en) 2021-10-14
CL2022002365A1 (es) 2023-02-03
IL296072A (en) 2022-11-01
US20240293531A1 (en) 2024-09-05
ZA202209826B (en) 2023-05-31
CN115768469A (zh) 2023-03-07
EP3955959A2 (en) 2022-02-23
ECSP22072590A (es) 2022-10-31
KR20220164500A (ko) 2022-12-13
CO2022013715A2 (es) 2022-12-30
AU2021253605A1 (en) 2022-10-06
JP2023520521A (ja) 2023-05-17
BR112022020100A2 (pt) 2022-11-29

Similar Documents

Publication Publication Date Title
WO2021204825A3 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
MX2018007627A (es) Vacuna contra el virus del zika.
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
MX344596B (es) Vacuna de subunidad recombinante del virus del dengue.
MX2015002483A (es) Composiciones inmunogenicas.
PH12018500305A1 (en) Multivalent vlp conjugates
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
SG10201811190SA (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
CO2022017989A2 (es) Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
MX2022012447A (es) Vacuna inactivada contra el virus sars-cov-2.
EA202190914A1 (ru) Иммуногенные композиции
PH12016502529A1 (en) Influenza vaccine nasal vaccination system
ZA202207115B (en) Viral vaccine compositions and methods of preparations thereof
MX2023004016A (es) Vacunas de poliepitopo del herpesvirus.
AR121752A1 (es) VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2024068265A3 (en) Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
WO2022256637A3 (en) Synthetic dna vaccine immunogenic improvements
MX2023000097A (es) Adyuvantes de vacunas y metodos de sintetizacion y uso de estos.
ZA202300164B (en) Modified alphavirus for use as covid-19 vaccine
BR112022002082A2 (pt) Formulações de vacina contra o chikungunya
CL2020002568A1 (es) Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv
EA202090386A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ГЕТЕРОЛОГИЧНЫХ репРНК ИММУНИЗАЦИЙ